Latest news with #Outcomes4Me
Yahoo
3 days ago
- Business
- Yahoo
Outcomes4Me Acquires Germany's Mika Health App to Accelerate AI-Driven Patient Empowerment Globally
Mika's cancer app is a certified medical device clinically proven to help cancer patients cope with both the physical and psychological effects of their diagnosis BOSTON and BERLIN, June 12, 2025 /PRNewswire/ -- Outcomes4Me Inc., the developer of the leading, direct-to-patient, AI-driven platform transforming the cancer-care experience, announced today that its German affiliate Outcomes4Me Germany GmbH has acquired the assets associated with the Mika Health app from Berlin-based Fosanis GmbH. The Mika app has served over 100,000 cancer patients globally, and is a clinically validated platform proven in clinical trials to reduce a range of symptoms associated with cancer care including depression, anxiety, and fatigue. Outcomes4Me, which supports more than 280,000 cancer patients, recently finalized a $21M funding round, emphasizing the company's plans to expand both its patient community and commercial business globally. This acquisition strengthens Outcomes4Me's platform with Mika's proven interventions for real-time symptom management, behavioral coaching, and emotional support, setting a new global standard for digital oncology support. It also allows Outcomes4Me to scale faster in European markets, leveraging Mika's regulatory readiness as MDR IIa-certified medical device and local partnerships. "With this acquisition, we're taking a major step toward our mission to make cancer understandable and manageable to every patient wherever and whomever they are," said Maya Sc.D., Founder and CEO of Outcomes4Me. "Mika's proven AI-driven emotional support technology and European footprint complement our evidence-based platform grounded in clinical guidelines and U.S. footprint. Together, we're building the most comprehensive digital companion for cancer patients worldwide." "Joining forces with Outcomes4Me allows us to take our vision further, faster," said Gandolf Finke, Ph.D., Founder and Managing Director of Fosanis GmbH. "We're excited to integrate our technology with a partner that shares our values of transparency, trust, and patient empowerment. The overlap in our customer base of global pharmaceutical companies that prioritize innovation and whole-patient care creates many synergies and allows us to immediately deliver combined value for our patients and business partners alike. For our patients using Mika, this transaction has no impact in terms of service they can expect." Outcomes4Me will exhibit at HLTH Europe in Amsterdam from June 16-19, 2025. Visit Outcomes4Me and Mika in the AI Spotlight pavilion at booth #F70-2. About Outcomes4MeOutcomes4Me is the first and leading end-to-end, AI-driven patient empowerment platform that helps patients with cancer take a proactive approach to their care from diagnosis throughout every stage of life and care. Its direct-to-patient platform integrates clinical guidelines, genomics, trial matching, and symptom tracking to help patients navigate through a cancer diagnosis with confidence and clarity. Through its patented technology, Outcomes4Me is redefining cancer care by delivering smarter, AI-powered solutions that put patients in control of their treatment decisions. What sets Outcomes4Me apart is its ability to generate unique, at-scale proprietary datasets that enable more precise and actionable insights for better patient outcomes. Based in Boston, Massachusetts, Outcomes4Me is a woman-led company of seasoned healthcare, oncology, pharmaceutical, consumer and technology veterans. For more information, visit About Mika HealthMika Health is an app-based platform aimed at providing targeted and comprehensive support to people with cancer using digital technology. Through scientifically proven methods and techniques of therapy management, the Digital Therapeutics (DTx) helps patients to actively participate in their treatment and regain more quality of life - with daily symptom monitoring, psychologically oriented coaching courses, and AI-supported, personalized recommendations. To achieve this, Mika combines innovative machine learning technologies with a multimedia knowledge database of rigorously verified content, such as nutritional tips, exercise routines, or mindfulness training. For more information, visit View original content: SOURCE Outcomes4Me Inc.
Yahoo
29-05-2025
- Business
- Yahoo
Outcomes4Me Secures $21M in Funding to Accelerate AI-Driven Innovation and Drive Global Expansion to Transform Cancer Care
BOSTON, May 29, 2025 /PRNewswire/ -- Outcomes4Me Inc., the developer of the leading direct-to-patient, AI-driven platform transforming the cancer care experience, today announced the close of a $21M funding round. "AI will reshape cancer care, and this investment accelerates our ability to deliver personalized treatments and improved outcomes to patients at scale," said Maya R. Said, Sc.D., Founder and CEO of Outcomes4Me. "With more than 280,000 cancer patients using our AI-enabled platform, we're not just offering people diagnosed with cancer a tool, we're empowering them with intelligent, real-time insights that guide them through every step of their care. This funding will help us further enhance our platform, expand our reach, and drive meaningful revenue growth." With this round, Outcomes4Me welcomes new investor London-based Salica Investments, with participation from all existing investors: Labcorp Venture Fund, Forecast Labs, Northpond Ventures, Sierra Ventures, Asset Management Ventures, IRA Capital, and Merstal LTD, bringing Outcomes4Me's total capital raised to date to $38M. AI at the Core of Cancer Care The future of cancer care is digital, data-driven, and deeply personalized. Outcomes4Me's AI-driven platform integrates real-time clinical guidelines, genomic insights, medication and symptom tracking, clinical trial matching, and patient peer communities into a single, easy-to-use interface for patients with cancer. By combining cutting-edge AI with deep oncology expertise and generating new multimodal patient-level data enriched at the drug level, Outcomes4Me is uniquely positioned to accelerate the pace of innovation in cancer care, driving both improved patient outcomes and sustainable revenue growth. "Outcomes4Me is an AI-driven pioneer in the oncology space, scaling rapidly in a market that demands smarter, personalized healthcare solutions," said Amy Summy, Executive Vice President, Chief Marketing Officer and Consumer Lead for Labcorp. "We are excited to support their digital platform as part of our deep commitment to help advance oncology care and improve patient outcomes." Track Record of Success Outcomes4Me's business is focused on accelerating innovation and improving outcomes by partnering with life sciences companies to help them reach the right patient at the right time with the right action. Since its commercial launch in 2022, the company has been on an incredible revenue growth trajectory, reflecting the increasing demand for smarter, more personalized cancer-care solutions. Notably, seven out of the top 10 global cancer pharmaceutical companies are already among Outcomes4Me's valued customers, further demonstrating its market leadership. Outcomes4Me's innovation has been widely recognized, generating more than 15 industry awards in the past three years, including being named a Fast Company World Changing Idea. Most recently, the company ranked #12 on the Inc. Regionals Northeast 2025 list, jumping from #70 the previous year, and the 2025 EY Entrepreneur of the Year program for the New England region named Outcomes4Me Founder and CEO Dr. Maya R. Said a finalist. An independent peer-reviewed study published in Current Oncology identified Outcomes4Me as the highest quality application among over 3,000 applications for adults with cancer worldwide. Revenue Growth and Global Expansion: A Key Focus for the Future As part of its trajectory to become the leading global digital health solution for cancer care, Outcomes4Me is making strategic moves toward expanding internationally with a goal to make a profound impact on global cancer care standards. With this new funding, Outcomes4Me will: Accelerate its market penetration across a broader range of cancer types, geographies, and global markets Leverage its proprietary datasets and expand its AI capabilities to drive even more precise, real-time personalized treatment recommendations Strengthen and scale its collaborations with top-tier health systems and life sciences companies globally Scale its revenue streams through new partnerships, international expansion, and innovative business models Drive outcomes-based evidence generation and real-world data insights for improved treatment and care About Outcomes4Me Outcomes4Me is the first and only end-to-end, AI-driven patient empowerment platform that helps patients with cancer take a proactive approach to their care from diagnosis throughout every stage of life and care. Its direct-to-patient platform integrates clinical guidelines, genomics, trial matching, and symptom tracking to help patients navigate through a cancer diagnosis with confidence and clarity. Through its patented technology, Outcomes4Me is redefining cancer care by delivering smarter, AI-powered solutions that put patients in control of their treatment decisions. What sets Outcomes4Me apart is its ability to generate unique, at-scale proprietary datasets that enable more precise and actionable insights for better patient outcomes. Based in Boston, Massachusetts, Outcomes4Me is a woman-led company of seasoned healthcare, oncology, pharmaceutical, consumer and technology veterans. For more information, visit View original content: SOURCE Outcomes4Me Inc.
